BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 10365151)

  • 1. Matrix metalloproteinases and their inhibitors.
    Kugler A
    Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma.
    Kugler A; Hemmerlein B; Thelen P; Kallerhoff M; Radzun HJ; Ringert RH
    J Urol; 1998 Nov; 160(5):1914-8. PubMed ID: 9783985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
    Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
    Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
    J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y; Koda M; Murawaki Y
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T; Okada Y; Nakanuma Y
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells.
    Janowska-Wieczorek A; Marquez LA; Matsuzaki A; Hashmi HR; Larratt LM; Boshkov LM; Turner AR; Zhang MC; Edwards DR; Kossakowska AE
    Br J Haematol; 1999 May; 105(2):402-11. PubMed ID: 10233411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
    Jones JL; Glynn P; Walker RA
    J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].
    Matsumoto F; Uzuki M; Kaneko C; Rikimaru A; Kokubun S; Sawai T
    Ryumachi; 1997 Oct; 37(5):688-95. PubMed ID: 9396371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy.
    Webster L; Chignell AH; Limb GA
    Exp Eye Res; 1999 Jan; 68(1):91-8. PubMed ID: 9986746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
    Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
    Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
    Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
    J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.